-transparent.png){kind=logo}
Oral lichenoid reaction, an immune-related adverse event of immunotherapy, has been reported in very few patients receiving anti-programmed cell death receptor-1 (anti-PD-1) therapy. Here, we describe a case of severe stomatitis (grade ≥3 by the Common Terminology Criteria for Adverse Events, version 4.0) accompanied by pharyngolaryngitis that was observed in a patient receiving nivolumab therapy. The stomatitis was diagnosed as drug-induced lichenoid reaction. Nivolumab therapy was discontinued, and the patient was administered systemic prednisolone (1mg/kg). Most of the patient's mucosal changes in the oral cavity and pharyngolarynx resolved within approximately 3 weeks after starting the prednisolone. Clinicians should be aware that severe oral lichenoid reactions can occur in patients receiving anti-PD-1 therapy.
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
January 2023,
SAGE open medical case reports,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
November 1988,
Dental journal of Malaysia,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
January 1990,
Journal of the California Dental Association,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
August 2020,
Dermatopathology (Basel, Switzerland),
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
October 2001,
Cutis,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
November 2011,
Allergy,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
October 2021,
International journal of dermatology,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
January 2017,
JAAD case reports,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
November 2020,
Oral surgery, oral medicine, oral pathology and oral radiology,
Y Enomoto, and
H Nakatani, and
S Kondo, and
T Kasai, and
Y Tsuchiya
February 1990,
Avances en odontoestomatologia,
